ST. PAUL, Minn., Oct. 8 /PRNewswire/ -- Brennen Medical, LLC a leader in biomaterial technology announces the nationwide availability of its XenMatriX(R) product for soft tissue reconstruction. Brennen Medical received clearance to market XenMatriX(R), via the FDA 510k process, into the surgical hernia market. Surgeons are successfully implanting XenMatriX in ventral hernia/abdominal wall procedures, including complex repairs.
XenMatriX(R) is designed for use in the treatment of abdominal wall (hernia) repair where the connective tissue has ruptured. With the aging population and the obesity epidemic, over 30% of people over the age of 55 will seek treatment for soft tissue reinforcement. XenMatriX offers a successful alternative to synthetic materials for this population in need of surgical intervention.
XenMatriX(R) employs a patented technology that maintains an acellular, structurally intact, non-crosslinked porcine dermal matrix for enhanced biocompatibility in host tissue. This non-crosslinked dermal matrix supports tissue revascularization, remodeling and regeneration for abdominal wall and hernia repairs. The compatibility and strength of this material minimizes hernia recurrence and pain, which also minimizes expense for both the patient and the healthcare environment.
Phillip Lawin, President of Brennen Medical said, "We are extremely pleased with the outcomes of XenMatriX. Unlike traditional mesh products, XenMatriX(R) can be used successfully in contaminated or potentially contaminated and complex fields. This provides patients and surgeons a truly safe and effective alternative for abdominal wall hernia repair."
About Brennen Medical
Brennen Medical is a world leader providing biologic porcine xenograft for use in plastic reconstructive, general surgical, burn, trauma, wound, urogynecological and orthopedic soft tissue repair procedures. Demonstrated to be effective, surgeons have used Brennen's proprietary porcine technologies for over 40 years. Mediskin(TM)and EZ Derm(TM), XenMatriX(R), and DermMatrix(R) provide the basis for innovation and quality to guide the Company's initiatives for a growing biosurgical market. Based in St. Paul, MN and privately held, the products are sold through a direct sales force and through partnerships with major medical device companies. In addition to porcine, Brennen also markets a line of products containing beta glucan, a natural complex carbohydrate providing improved wound healing and host tissue regeneration. The company maintains a web site at http://www.brennenmed.com.
CONTACT: Phil Lawin of Brennen Medical, LLC, 1-800-328-9105,
plawin@brennenmed.com
Web site: http://www.brennenmed.com/
